Seth M. Cohen
2018; Wiley; Volume: 57; Issue: 31 Linguagem: Inglês
10.1002/anie.201803126
ISSN1521-3773
Tópico(s)Carbon dioxide utilization in catalysis
ResumoAngewandte Chemie International EditionVolume 57, Issue 31 p. 9586-9586 Author ProfileFree Access Seth M. Cohen First published: 19 April 2018 https://doi.org/10.1002/anie.201803126AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Graphical Abstract “The natural talent I would like to be gifted with is to be a fantastic musician (piano, guitar, drums). My motto is ‘Do. Or do not. There is no try'. OK, this is actually Yoda's motto, but I like it …” Find out more about Seth M. Cohen in his Author Profile. Seth M. Cohen The author presented on this page has recently published his 10th article in Angewandte Chemie in the last 10 years: “A Metal–Organic Framework with Exceptional Activity for C−H Bond Amination”: L. Wang, D. W. Agnew, X. Yu, J. S. Figueroa, S. M. Cohen, Angew. Chem. Int. Ed. 2018, 57, 511; Angew. Chem. 2018, 130, 520. Date of birth: July 14, 1972 Position: Professor of Chemistry and Biochemistry, University of California San Diego E-mail: scohen@ucsd.edu Homepage: cohenlab.ucsd.edu ORCID: 0000-0002-5233-2280 Education: 1994 BS, BA, Stanford University 1998 PhD supervised by Kenneth N. Raymond, University of California, Berkeley 1999–2001 Postdoctoral fellow supervised by Stephen J. Lippard, MIT Awards: 2008 AAAS Roger Revelle Fellowship in Global Stewardship; 2016 ACS Arthur C. Cope Scholar Award; 2017 RCSA TREE Award Research: Inorganic, bioinorganic, medicinal, and materials chemistry Hobbies: Classic and exotic automobiles, movies, US politics The natural talent I would like to be gifted with is to be a fantastic musician (piano, guitar, drums). My motto is “Do. Or do not. There is no try”. OK, this is actually Yoda's motto, but I like it. When I was eighteen I wanted to be an astronaut in space or a field biologist in the wild. If I could be anyone for a day, I would be Bono (on a sold-out concert night of course!). Or anyone currently on the International Space Station (ISS). The most important future applications of my research are addressing pressing needs in human health by the development of new metalloenzyme inhibitors through the startup company I co-founded, Forge Therapeutics. If I were a car I would be too many to choose from – 1957 Chevy Nomad, 1963 Studebaker Avanti, 1963 ‘Split Window’ Corvette, 1968 Plymouth Roadrunner, 1970 Ferrari Dino, 1972 DeTomaso Pantera, 2006 Dodge Viper SRT10, 2006 Ford GT—this is becoming a wish list … My favorite quote is “I have been—and shall always be—your friend.” Mr. Spock, Star Trek II, The Wrath of Khan. If I could be any age I would be 21. Need I say more? I advise my students to read the literature carefully, be passionate about your work, and follow your dreams. The secret of being a successful scientist is loving what you do (and a lot of hard work). My favorite principle is Kiri-kin-tha's First Law of Metaphysics: “Nothing unreal exists”. Star Trek IV: The Voyage Home. In the future I see myself “Difficult to see. Always in motion is the future.” OK, that's Yoda again. My 5 top papers: 1“Potent, Selective Pyrone-Based Inhibitors of Stromelysin-1”: D. T. Puerta, J. Mongan, B. L. Tran, J. A. McCammon, S. M. Cohen, J. Am. Chem. Soc. 2005, 127, 14148. (A critical demonstration that we could develop metalloenzyme inhibitors using novel metal-binding pharmacophores.) 2“Postsynthetic Covalent Modification of a Neutral Metal–Organic Framework”: Z. Wang, S. M. Cohen, J. Am. Chem. Soc. 2007, 129, 12368. (Arguably the most important paper of my career to date, detailing our first report of postsynthetic modification of a MOF.) 3“Photochemical Activation of a Metal–Organic Framework to Reveal Functionality”: K. K. Tanabe, C. A. Allen, S. M. Cohen, Angew. Chem. Int. Ed. 2010, 49, 9730; Angew. Chem. 2010, 122, 9924. (Perhaps my favorite example of MOF postsynthetic modification, using photochemistry to deprotect catechol groups within a MOF.) 4“Identifying Chelators for Metalloprotein Inhibitors Using a Fragment-Based Approach”: J. A. Jacobsen, J. L. Fullagar, M. T. Miller, S. M. Cohen, J. Med. Chem. 2011, 54, 591. (Our first complete description of combining bioinorganic chemistry and fragment-based drug discovery.) 5“polyMOFs: A New Class of Interconvertible Polymer-Metal-Organic-Framework Hybrid Materials”: Z. Zhang, H. T. H. Nguyen, S. A. Miller, S. M. Cohen, Angew. Chem. Int. Ed. 2015, 54, 6152; Angew. Chem. 2015, 127, 6250. (I was so surprised and excited that the concept of polyMOFs actually worked and I was thrilled to collaborate with my best friend from college, Prof. Stephen A. Miller). Volume57, Issue31July 26, 2018Pages 9586-9586 ReferencesRelatedInformation
Referência(s)